{"title":"Newly designed nanoparticle-drug delivery systems against <i>Staphylococcus aureus</i> infection: a systematic review.","authors":"Farideh Kamarehei, Goran Noori Saleh, Jaber Hemmati, Saeedeh Gohari","doi":"10.62347/BVWH1940","DOIUrl":null,"url":null,"abstract":"<p><p>A nanoparticle-drug delivery system against <i>Staphylococcus aureus</i>, especially <i>Methicillin-resistant staphylococcus aureus</i>, has been recently proposed as an alternative pathway therapy. <i>Methicillin-resistant staphylococcus aureus</i> is resistance to many antibiotics, making it a a threat to human life, especially for older and immunocompromised people. Treatment of <i>Multidrug-resistant staphylococcus aureus</i> is considered an urgent need. A variety of kinds of nanoparticle-drug delivery systems with different compositions, and biological properties have been extensively investigated against <i>Staphylococcus aureus</i>. This review summarizes the novel nanoparticle-drug delivery systems against <i>Staphylococcus aureus</i>. These nanoparticle-drug delivery systems could reduce antibiotic resistance and minimize side effects of the antibiotics. Also, they can deliver a high concentration of the drugs and eliminate the bacteria in a specific and targeted site of infection. Despite these benefits of nanoparticle-drug delivery systems, the cytotoxicity, stress oxidative, genotoxicity, and inflammation that may occur <i>in vivo</i> and <i>in vitro</i> should not be ignored. Therefore, we need a better knowledge of the pharmacological properties and safety concerns of nanoparticle-drug delivery systems. The limitations of each nanoparticle-drug delivery system with high therapeutic potential have to be considered for further design.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11070434/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of clinical and experimental pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/BVWH1940","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
A nanoparticle-drug delivery system against Staphylococcus aureus, especially Methicillin-resistant staphylococcus aureus, has been recently proposed as an alternative pathway therapy. Methicillin-resistant staphylococcus aureus is resistance to many antibiotics, making it a a threat to human life, especially for older and immunocompromised people. Treatment of Multidrug-resistant staphylococcus aureus is considered an urgent need. A variety of kinds of nanoparticle-drug delivery systems with different compositions, and biological properties have been extensively investigated against Staphylococcus aureus. This review summarizes the novel nanoparticle-drug delivery systems against Staphylococcus aureus. These nanoparticle-drug delivery systems could reduce antibiotic resistance and minimize side effects of the antibiotics. Also, they can deliver a high concentration of the drugs and eliminate the bacteria in a specific and targeted site of infection. Despite these benefits of nanoparticle-drug delivery systems, the cytotoxicity, stress oxidative, genotoxicity, and inflammation that may occur in vivo and in vitro should not be ignored. Therefore, we need a better knowledge of the pharmacological properties and safety concerns of nanoparticle-drug delivery systems. The limitations of each nanoparticle-drug delivery system with high therapeutic potential have to be considered for further design.
期刊介绍：
The International Journal of Clinical and Experimental Pathology (IJCEP, ISSN 1936-2625) is a peer reviewed, open access online journal. It was founded in 2008 by an international group of academic pathologists and scientists who are devoted to the scientific exploration of human disease and the rapid dissemination of original data. Unlike most other open access online journals, IJCEP will keep all the traditional features of paper print that we are all familiar with, such as continuous volume and issue numbers, as well as continuous page numbers to keep our warm feelings towards an academic journal. Unlike most other open access online journals, IJCEP will keep all the traditional features of paper print that we are all familiar with, such as continuous volume and issue numbers, as well as continuous page numbers to keep our warm feelings towards an academic journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
